A detailed history of Semmax Financial Advisors Inc. transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Semmax Financial Advisors Inc. holds 90 shares of BMY stock, worth $5,220. This represents 0.0% of its overall portfolio holdings.

Number of Shares
90
Previous 89 1.12%
Holding current value
$5,220
Previous $3,000 33.33%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$39.66 - $51.75 $39 - $51
1 Added 1.12%
90 $4,000
Q2 2024

Aug 14, 2024

BUY
$40.25 - $52.99 $40 - $52
1 Added 1.14%
89 $3,000
Q1 2024

May 16, 2024

BUY
$47.98 - $54.4 $47 - $54
1 Added 1.15%
88 $4,000
Q4 2023

Feb 14, 2024

BUY
$48.48 - $57.85 $96 - $115
2 Added 2.35%
87 $4,000
Q3 2023

Nov 14, 2023

BUY
$57.89 - $64.73 $173 - $194
3 Added 3.66%
85 $4,000
Q2 2022

Aug 12, 2022

BUY
$72.62 - $79.98 $72 - $79
1 Added 1.23%
82 $6,000
Q1 2022

May 11, 2022

BUY
$61.48 - $73.72 $61 - $73
1 Added 1.25%
81 $6,000
Q4 2021

Mar 01, 2022

BUY
$53.63 - $62.52 $4,290 - $5,001
80 New
80 $5,000
Q2 2020

Jul 17, 2020

SELL
$54.82 - $64.09 $2,686 - $3,140
-49 Closed
0 $0
Q4 2019

Feb 03, 2020

BUY
$49.21 - $64.19 $2,411 - $3,145
49 New
49 $3,000
Q3 2019

Nov 07, 2019

SELL
$42.77 - $50.71 $1,625 - $1,926
-38 Closed
0 $0
Q2 2019

Aug 07, 2019

SELL
$44.62 - $49.34 $10,173 - $11,249
-228 Reduced 85.71%
38 $2,000
Q1 2019

May 07, 2019

SELL
$45.12 - $53.8 $306,635 - $365,624
-6,796 Reduced 96.23%
266 $13,000
Q4 2018

Feb 14, 2019

BUY
$48.76 - $63.23 $344,343 - $446,530
7,062 New
7,062 $367,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $123B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Semmax Financial Advisors Inc. Portfolio

Follow Semmax Financial Advisors Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Semmax Financial Advisors Inc., based on Form 13F filings with the SEC.

News

Stay updated on Semmax Financial Advisors Inc. with notifications on news.